Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2833

Sort by

Sort Order Select

Journal Articles

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood (2025) 146 (21): 2544–2560.

https://doi.org/10.1182/blood.2024026919

Published: 2025

Includes: Supplemental data

Journal Articles

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Wassilis S. C. Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L. B. M. Korst, A. Vera de Jonge, Christie P. M. Verkleij, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola M. Homan-Weert, Pieter Sonneveld, Philippe Moreau, Jürgen Claesen, Niels W. C. J. van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2025) 146 (21): 2517–2530.

https://doi.org/10.1182/blood.2025028587

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G. M. Durie, Robert Z. Orlowski

Blood (2025) 146 (21): 2507–2516.

https://doi.org/10.1182/blood.2024027962

Published: 2025

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (20): 2392–2405.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL

Blood (2025) 146 (20): 2417–2427.

https://doi.org/10.1182/blood.2025029785

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Mantle cell lymphoma with KMT2A rearrangement

Shimin Hu, Guilin Tang

Blood (2025) 146 (20): 2491.

https://doi.org/10.1182/blood.2025030135

Published: 2025

Journal Articles

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Blood (2025) 146 (19): 2350–2356.

https://doi.org/10.1182/blood.2025028985

Published: 2025

Includes: Supplemental data

Journal Articles

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

Debasmita Dutta, Jiye Liu, Kenneth Wen, Arghya Ray, Alessandro Salatino, Xiangdong Liu, Annamaria Gulla, Teru Hideshima, Yan Song, Kenneth C. Anderson

Blood (2025) 146 (19): 2322–2335.

https://doi.org/10.1182/blood.2025028597

Published: 2025

Includes: Supplemental data

Journal Articles

Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell–type chronic active EBV infection

Blood (2025) 146 (19): 2336–2349.

https://doi.org/10.1182/blood.2024026805

Published: 2025

Includes: Supplemental data

Journal Articles

Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma

Ibrahim Elsharawi, Sorin Selegean

Blood (2025) 146 (19): 2370.

https://doi.org/10.1182/blood.2025029949

Published: 2025

Journal Articles

PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism

Cecilia Bonolo De Campos, Ruijuan He, Tessa Josephine Pelino, Dor David Abelman, Zhihua Li, Daniel K C Lee, Ding Yan Wang, Michael St. Paul, Jeffrey Bruce, Craig D Simpson, Leanne Wybenga-Groot, Michael F. Moran, Rodger E Tiedemann, Trevor Pugh, Tak W. Mak, Olga Issakova, Nikolai Sepetov, Suzanne Trudel, A Keith Stewart

Blood blood.2025030061.

https://doi.org/10.1182/blood.2025030061

Published: 2025

Includes: Supplemental data

Journal Articles

Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?

Christian Peter Jaworek, Paul J Bröckelmann

Blood blood.2025029935.

https://doi.org/10.1182/blood.2025029935

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

α-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development

Carine Jaafar, Purushoth Ethiraj, Zhijun Qiu, An-Ping Lin, Pedro S. S. M. Ferrari, Ricardo C. T. Aguiar

Blood (2025) 146 (18): 2217–2228.

https://doi.org/10.1182/blood.2024028069

Published: 2025

Includes: Supplemental data

Journal Articles

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers E. M. Patten, Sebastian Grosicki, Helen McCarthy, Fritz Offner, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps

Blood (2025) 146 (18): 2168–2176.

https://doi.org/10.1182/blood.2024028205

Published: 2025

Includes: Supplemental data

Journal Articles

Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency

Jianli Tao, Luca Alessandri, Alessandro Gasparetto, Lijuan Zhao, Xuefei Zhang, Frederick W. Alt, Roberto Chiarle

Blood (2025) 146 (18): 2203–2216.

https://doi.org/10.1182/blood.2024026131

Published: 2025

Includes: Supplemental data

Journal Articles

Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma

Madhavi Pandiri, Daniel A. Arber

Blood (2025) 146 (18): 2272.

https://doi.org/10.1182/blood.2025030204

Published: 2025

Journal Articles

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition

Blood blood.2025031086.

https://doi.org/10.1182/blood.2025031086

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Mantle cell lymphoma with KMT2A rearrangement

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell–type chronic active EBV infection

Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma

PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism

Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

α-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency

Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only